TCGA-D8-A1XK-01A-21R-A14M-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 15
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.690
- G2M_CHECKPOINT+0.590
- MYC_TARGETS_V1+0.560
- MYC_TARGETS_V2+0.540
- MTORC1_SIGNALING+0.510
- UNFOLDED_PROTEIN_RESPONSE+0.420
- INFLAMMATORY_RESPONSE+0.390
- TNFA_SIGNALING_VIA_NFKB+0.390
- IL6_JAK_STAT3_SIGNALING+0.380
- ALLOGRAFT_REJECTION+0.370
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.410
- BILE_ACID_METABOLISM-0.280
- ADIPOGENESIS-0.260
- MYOGENESIS-0.250
- COAGULATION-0.240
- FATTY_ACID_METABOLISM-0.230
- XENOBIOTIC_METABOLISM-0.200
- UV_RESPONSE_DN-0.180
- APICAL_JUNCTION-0.170
- APICAL_SURFACE-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-C8-A27B-01A-11R-A169-07 | — | E | 0.882 |
| 2 | TCGA-A2-A0CM-01A-31R-A034-07 | — | E | 0.862 |
| 3 | BS_84XCR9GG | high-grade glioma | — | 0.858 |
| 4 | 568a845e-d8a0-47b5-af77-896831524b16 | — | — | 0.840 |
| 5 | SRR12475159 | — | — | 0.835 |
| 6 | TCGA-AR-A1AI-01A-11R-A12P-07 | — | E | 0.834 |
| 7 | TCGA-PQ-A6FI-01A-11R-A31N-07 | — | — | 0.828 |
| 8 | TCGA-FD-A3B6-01A-21R-A20F-07 | — | — | 0.827 |
| 9 | TCGA-E2-A14N-01A-31R-A137-07 | — | E | 0.824 |
| 10 | SRR1313135 | — | C | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.690 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.590 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.510 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.420 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.390 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.370 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.260 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.230 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.220 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |